On Friday, Seventy Seven Energy Inc. (NYSE:SSE)’s shares gained 3.64% to $4.56, while its weekly performance remained better, showing an upward trend up to 19.37%.
Seventy Seven Energy, has scheduled to release its 2015 first quarter operational update and financial results before market open on Tuesday, May 5, 2015. A conference call to discuss the results has been scheduled for the same day at 9:00 a.m. CDT. The telephone number to access the conference call is U.S. toll-free 844-867-9749 and international 901-300-3300. The conference ID for the call is 22784240. We encourage those who would like to participate in the call to place calls between 8:50 – 9:00 a.m. CDT.
Seventy Seven Energy Inc. provides oilfield services in the United States. The company operates in four segments: Drilling, Hydraulic Fracturing, Oilfield Rentals, and Oilfield Trucking. The Drilling segment offers land drilling and drilling-related services, counting directional drilling for the oil and natural gas exploration and development activities. The Hydraulic Fracturing segment provides hydraulic fracturing and other well stimulation services.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s shares surged 6.89% to $37.53, during the last trading session on Friday, while its weekly performance remained better, showing an upward trend up to 19.18%.
ACADIA Pharmaceuticals, declared that it will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015, at 9:20 a.m. Eastern Time in New York City.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead product candidate is NUPLAZID, which accomplished the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis; is in Phase II study for Alzheimer’s disease psychosis; and has accomplished Phase II trial for the treatment of schizophrenia.
At the end of Friday’s trade, Civeo Corporation (NYSE:CVEO)’s shares gained 3.26% to $3.48, while its weekly performance remained better, showing an upward trend up to 19.18%.
Formerly on March 26, Civeo Corporation declared that it has won a contract extension at its Wapasu Creek location.
Under the contract, which now extends through the end of 2017, Civeo will continue to provide accommodations and other services to a key customer at its Wapasu Creek location in Alberta, Canada for about 500 rooms on average. The extension is valued at a minimum of C$31 million with the potential for further room demand from the customer.
This extension reduces the uncontracted proceed for the fourth quarter of 2015 comprised of in the Company’s full year 2015 guidance for proceed and EBITDA.
The Wapasu Creek Lodge is the Company’s largest location and features 5,174 standard and deluxe rooms, equipped with Internet and cable TV. The Company offers catering, personnel logistical services, fitness and recreation facilities and a Tim Horton’s, with a focus on the guest experience, striving to make working away from home healthier and more productive.
Civeo Corporation provides remote site accommodations for the natural resource industry in Australia, Canada, and the United States. It also offers facility administration services, counting food services; customized facility administration information systems that provide clients with the tools and information necessary to manage the allocation of contracted rooms and service days; and support services, such as housekeeping and janitorial services, facility maintenance, laundry, communications, supply chain and logistics administration, power generation, and transportation and personnel logistics.
Curis, Inc. (NASDAQ:CRIS), ended its Friday’s trading session with -0.36% loss, and closed at $2.80, while its weekly performance remained better, showing an upward trend up to 19.15%.
This week, Curis, declared that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead proprietary drug candidate, CUDC-907 for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL).
CUDC-907 is an oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is presently under investigation in Phase 1 clinical studies in patients with relapsed or refractory lymphomas or multiple myeloma in addition to in patients with advanced/ relapsed solid tumors, counting hormone receptor positive (HR+)/ HER2-negative breast cancer or midline carcinoma with certain NUT gene rearrangements.
The FDA’s Orphan Drug Designation program grants orphan status to drugs and biologics that are intended for use in rare diseases/ or disorders, defined as those that affect fewer than 200,000 people in the U.S. or that affect more than 200,000 people in the U.S. where there is no reasonable expectation that the cost of developing and making the drug or biological product for the specific disease or condition will be recovered from sales in the U.S. Orphan drug designation may qualify the sponsor for financial incentives such as tax credits for qualified trials, the ability to apply for annual grant funding, clinical trial research design assistance and waiver of application fees associated with the approval of new drug under the Prescription Drug User Fee Act. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug or biological product for the same indication for a period of 7 years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or if the product with orphan exclusivity experiences a shortage. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
